Pharmaceuticals, Biotechnology and Life Sciences
Mylan and Lupin Limited have received from the European Commission (EC) marketing authorization for Nepexto, a biosimilar to Enbrel, for all indications of the reference product.
Mylan is potentially getting access to 14 indications after approval, as first neurotoxin formulation to be developed as a potential biosimilar product to BOTOX.
Mylan said on Friday that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi’s Lantus® SoloSTAR® device patents, U.S. Patent Nos. 8,603,044, 8,992,486, and 9,526,844 unpatentable.
Revance, Mylan Biosimilar to Botox postpon program decision to aftr April
Mylan and Biocon have launched Fulphila, a biosimilar to Neulasta (pegfilgrastim), as it was approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
Glenmark Pharmaceuticals said Tuesday it has bagged the final USFDA’s approval for its generic version of Mylan’s Olux-E Foam, Clobetasol Propionate Foam.
Mylan’s second quarter performance was strong as the company has delivered or exceeded on expectations across all financial metrics, the company’s CEO Heather Bresch said in a press release Monday.
The European Commission has approved Mylan/Biocon’s co-developed biosimilar insulin glargine Semglee marketing authorization for people with diabetes after it got…
Mylan N.V. has launched its generic version of BMSs oncology drug Mutamycin in USA, called Mitomycin, for which it noted…
World’s largest HIV/AIDS drug-maker Mylan has received tentative approval for combination HIV treatment DTG/FTC/TAF under FDA’s PEPFAR program, the company…